

CURRICULUM VITAE

Alexandru Schiopu, MD PhD

ADDRESS

Internal medicine clinic, Skåne University Hospital Lund

Cardiovascular Research – Immunity and atherosclerosis
Department of Clinical Sciences Malmö, Lund University

EDUCATION AND EMPLOYMENT

Present position

2009- - Consultant in Internal Medicine, specialist in Cardiology - MAVA, Internal Medicine clinic, Skåne University Hospital Lund (25%)

- Principal Investigator, Cardiovascular Research – Immunity and atherosclerosis, Department of Clinical Sciences Malmö, Lund University (75%)

Specialist certification

2015 Internal medicine
2018 Cardiology

Docent (Associate Professor)

2014 Cardiology, Lund University

Postdoctoral positions

2006-2007 Visiting Scientist - Atherosclerosis Research Center, Cedars Sinai Medical Center, Los Angeles, USA; Prof. Prediman K. Shah

2007-2009 Post-doctoral Research Fellow – University of Oxford, Transplantation Research Immunology Group, John Radcliffe Hospital; Prof. Kathryn J. Wood

PhD degree

April 2006 Lund University, Experimental Cardiovascular Research
"Development of a passive immunization strategy against atherosclerosis"
Main supervisor: Prof. Gunilla Nordin Fredrikson

Higher education

2001 Medical doctor, Profile: General medicine
University of Medicine and Pharmacy of Tirgu-Mures, Romania

Previous employment

2009-2018 Resident doctor in Internal medicine and Cardiology, SUS
2007-2009 Postdoctoral Research Fellow - Transplantation Research Immunology Group, Oxford University, UK
2006-2007 Visiting Scientist - Cedars Sinai Medical Center, Los Angeles, USA
2002-2006 PhD student - Experimental Cardiovascular Research Unit, Lund University

2001-2002 Clinical Internship – University Hospital of Tirgu-Mures, Romania

ACADEMIC ACHIEVEMENTS

Research grants

2021 - 2023 Prince Daniel research grant for young promising researchers - Swedish Heart and Lung Foundation
 2022 NovoNordisk Foundation project grant
 2021 – 2024 Project grant – Vetenskapsrådet
 2021 – 2024 “Bundy Academy” research prize in Cardiology – Lund University
 2019 – 2024 Clinical research position (Forskartjänst) - Swedish Heart and Lung Foundation
 2016 – 2024 Swedish Heart and Lung Foundation - Project Grant
 2015 – 2022 ALF Project Grant
 2018 – 2022 “Research grant for complex collaborative projects” – the Romanian National Research Agency. In cooperation with Prof. Maya Simionescu och Prof. Dragos Vinereanu, Bucharest University (2 000 000 EUR)
 2019 – 2020 Regional research grant (Region Skåne)
 2019 - 2022 Skane University Hospital - stiftelser och donationer
 2019 – 2020 Inga och John Hains stiftelse för medicinsk forskning
 2015 – 2018 Clinical research position - Marianne och Marcus Wallenbergs Stiftelse (“Forskartjänst till klinisk verksamma läkare”)
 2014 – 2016 Research grant – ALF Innovative projects
 2014 “Bundy Academy” research prize in Cardiology – Lund University
 2015 – 2016 Research grant – Crafoord stiftelse
 2014 – 2015 Research grant – Lundströms stiftelse
 2014 – 2015 Research grant – Kungliga fysiografen
 2010 – 2015 Research grant - ALF ”Yngre forskare”
 2012 Research stipend - Esther Olssons stiftelse II och Anna Jönssons stiftelse
 2007 – 2009 Postdoctoral stipend – Swedish Research Council (VR)
 2002 – 2004 Doctoral stipend – Swedish Heart and Lung Foundation

Academic awards

2021 **“Erik K. Fernström”** prize for successful young promising researchers at Lund University
 2020 **“Lund University and Sparbanken Skåne’s Innovation Award”** – winner, best project
 2018 **“Rising star”** – Skane University Hospital Research Committee
 2017 **“Best Moderated Poster” award** – European Society of Cardiology Congress
 2006 **Visiting Scientist Award** - International Atherosclerosis Society
 2006 **Poster of Distinction** - Federation of Clin. Immunology Societies Congress
 2004 **Young Investigator Award** - European Atherosclerosis Society Congress

Supervision

2022 - Main supervisor – Anna Schuss, MD, PhD student, Lund University
 2020 - Main supervisor – Gabriel Jakobsson, PhD student, Lund University
 2017 - Main supervisor – Razvan Mares, MD, PhD student, UMF Tirgu-Mures
 2014 - Main supervisor – Troels Yndigegn, MD, PhD student, Lund University

- 2022 - Main supervisor – Dr. Jenifer Vallejo, post-doc, Lund University
- 2022 - Main supervisor – Dr. Greg Markby, post-doc, Lund University
- 2015 – 2019 Main supervisor – Dr. Margret Leosdottir, MD, post-doc, Lund University
- 2017 – 2021 Co-supervisor – Halldora Ögmundsdottir Michelsen, MD, PhD student, Lund University
- 2016 – 2020 Main supervisor – Helena Grauen Larsen, MD, PhD student, Lund University
- 2015 – 2019 Main supervisor – Dr. Goran Marinkovic, post-doc
- 2012 – 2015 Co-supervisor – Dr. Helena Grufman, PhD student, Lund University
- 2012 – 2015 Supervisor – 6 medical students, T5 and T10 research projects (201 – Andrée Romner, T10; 2015 - Emma Gustafsson, T10; 2014 - Erika Bergman, T5; 2014 - Emilia Kvist T5; 2013 - Julia Burlin, T10; 2012 - Petter Halling, T10)

Teaching

- 2022 - Placement coordinator (kursplatsansvarig) for term 6 medical students at Skane University Hospital Lund
- 2020 - Research supervisor (amanuens) Internal medicine – Term 6 medical students, Lund University
- 2019 - Leader “Patient interaction with translator” simulation
- 2014 - Course leader: “Applied biomedical research” (yearly)
- Masters Programme of Medico-Pharmaceutical Research, University of Medicine, Pharmacy, Science and Technology of Tirgu-Mures, Romania
- 2014 - Seminaries on cardiovascular disease - under the patronage of the Swedish Heart and Lung Foundation
- Nov 2012 PhD course “Vascular Biology and Disease” – in collaboration with Dr. Harry Björkbacka
- 2009 - Courses and seminars on Atherosclerosis, Coronary artery disease, Heart failure, Electrocardiography for medical students (Lund University) and dentistry students (Malmö University)

Reviewer assignments - Journals

JAMA Cardiology, Circulation, Annals of Internal Medicine, Journal of Neurological Sciences, BBA Molecular Cell Research, Frontiers in Cell and Developmental Biology, Frontiers in Cardiovascular Medicine, European Heart Journal Open, JACC: Basic to translational science

Editor assignments – Journals

Associate Editor – Frontiers in Cardiovascular Medicine

Review assignments – Grants

- 2012, 2016 The Executive Agency for Higher Education Research Development and Innovation Funding (UEFISCDI), Bucharest, Romania
- 2017 - Internal grants, University of Medicine and Pharmacy of Tirgu-Mures

Faculty opponent

- 2022 Tong Jiao, Karolinska Institutet, Dissertation opponent
- 2018 Ulrika Pahlm, LU – Member in the dissertation committee
- 2018 Sahar Tahvili, LU – Member in the dissertation committee
- 2017 Marcus Ulleryd, Gothenburg Univ. – Member in the dissertation committee
- 2017 Johan Thelin, PhD student – Half-time control opponent
- 2016 Patrik Gilje, LU – Member in the dissertation committee
- 2016 Cecilia Frej, LU – Member in the dissertation committee
- 2015 Helena Tydén, MD, PhD student – Half-time control opponent

Collaborations with the industry

- 2020 - Founder and CEO of Calprotect AB, Lund, Sweden – biotech start-up developing a treatment based on calprotectin blockade for myocardial infarction, myocarditis and sepsis patients
- 2021 - Principal Investigator in ZEUS – Novo Nordisk study testing the effects of antibody-based IL-6 blockade in myocardial infarction patients
- 2021 - Scientific advisor for Novo Nordisk
- 2019 - Scientific collaborations with Astra Zeneca and Cantargia AB
- 2002-2006 Conducted the pre-clinical testing of an antibody-based treatment against atherosclerosis, targeting specific ApoB peptides – collaboration with Bioinvent AB, Lund, Sweden

Publication list

Scopus: <https://www.scopus.com/authid/detail.uri?authorId=22135861300>

ORCID: <https://orcid.org/0000-0002-7587-5050>

References

Prof. Olle Melander
Lund University
Department of Clinical Sciences Malmö
E-mail: Olle.Melander@med.lu.se
Tel: +46 (0) 40 39 12 09

Prof. Kathryn Wood
University of Oxford
Transplantation Research Immunology
E-mail: Kathryn.Wood@nds.ox.ac.uk
Tel: +44 (0)1865 222508

Prof. Jan Nilsson
Lund University
Department of Clinical Sciences Malmö
E-mail: Jan.Nilsson@med.lu.se

PUBLICATION LIST

Original peer-reviewed articles

1. Ögmundsdottir Michelsen H, Sjölin I, Bäck M, Gonzalez M, Olsson A, Sandberg C, **Schiopu A**, Leosdottir M: Effect of a lifestyle-focused web-based application on risk factor management in post-myocardial infarction patients – a randomized controlled trial. *J Med Int Res*. 2022.
2. Ding Z, Du F, Averitt V RG, Jakobsson G, Rönnow CF, Rahman M, **Schiopu A**, Thorlacius H: Targeting S100A9 Reduces Neutrophil Recruitment, Inflammation and Lung Damage in Abdominal Sepsis. *Int. J. Mol. Sci*. 2021, 22(23), 12923.
3. Mihaila AC, Ciortan L, Macarie RD, Vadana M, Cecoltan S, Preda MB, Hudita A, Gan AM, Jakobsson G, Tucureanu MM, Simionescu M, **Schiopu A***, Butoi E*: Transcriptional profiling and functional analysis of N1/N2 neutrophils reveal an immunomodulatory effect of S100A9-blockade on the pro-inflammatory N1 subpopulation. *Front Immunol*. 2021 Aug 10;12:708770. *Shared last authorship
4. Yndigegn T, Gilje P, Dankiewicz J, Mokhtari A, Isma N, Holmqvist J, **Schiopu A**, Ravn-Fischer A, Hofmann R, Szummer K, Jernberg T, James SK, Gale CP, Fröbert O, Mohammad MA: Safety of Early hospital discharge following admission with ST-elevation myocardial infarction treated with percutaneous coronary intervention: a nationwide cohort study. *EuroIntervention*. 2021 Aug 3;EIJ-D-21-00501.
5. Marinković G, Koenis D, de Camp L, Jablonowski R, Graber N, de Waard V, de Vries C, Goncalves I, Nilsson J, Jovinge S, **Schiopu A**: S100A9 links inflammation and repair in myocardial infarction. *Circ Res*. 2020 Aug 14;127(5):664-676.
6. Sjölin I, Bäck M, Nilsson L, **Schiopu A**, Leosdottir M: Association between attending exercise-based cardiac rehabilitation and cardiovascular risk factors at one-year post myocardial infarction. *PLoS One*. 2020 May 11;15(5):e0232772.
7. Tomas L, Bengtsson E, Andersson L, Badn W, Tengryd C, Persson A, Edsfeldt A, Nilsson PM, **Schiopu A**, Nilsson J, Gonçalves I, Björkbacka H: Low Levels of CD4+CD28null T Cells at Baseline Are Associated With First-Time Coronary Events in a Prospective Population-Based Case-Control Cohort. *Arterioscler Thromb Vasc Biol*. 2020 Feb;40(2):426-436.
8. Ögmundsdottir Michelsen H, Sjölin I, Schlyter M, Hagström E, Kiessling A, Henriksson P, Held C, Hag E, Nilsson L, Bäck M, **Schiopu A**, Zaman MJ, Leosdottir M: Cardiac rehabilitation after acute myocardial infarction in Sweden - evaluation of programme characteristics and adherence to European guidelines: The Perfect Cardiac Rehabilitation (Perfect-CR) study. *Eur J Prev Cardiol*. 2020 Jan;27(1):18-27.
9. Georgakis MK, Malik R, Björkbacka H, Pana TA, Demissie S, Ayers C, Elhadad MA, Fornage M, Beiser AS, Benjamin EJ, Boekholdt MS, Engström G, Herder C, Hoogetveen RC, Koenig W, Melander O, Orho-Melander M, **Schiopu A**, Söderholm M, Wareham N, Ballantyne CM, Peters A, Seshadri S, Myint PK, Nilsson J, de Lemos

- JA, Dichgans M: Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals. *Circ Res.* 2019 Sep 27;125(8):773-782.
10. Marinković G, Grauen Larsen H, Yndigegn T, Szabo IA, Mares RG, de Camp L, Weiland M, Tomas L, Goncalves I, Nilsson J, Jovinge S, **Schiopu A**: Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction. *Eur Heart J.* 2019 Aug 21;40(32):2713-2723.
11. Grauen Larsen H, Yndigegn T, Marinkovic G, Grufman H, Mares GR, Nilsson J, Goncalves I, **Schiopu A**: The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event. *Atherosclerosis.* 2019 Aug; 287:16-23.
12. Grauen Larsen H, Marinkovic G, Nilsson PM, Nilsson J, Engström G, Mellander O, Orho-Mellander M, **Schiopu A**: High plasma sRAGE is associated with slower carotid intima media thickness progression and lower risk for first-time coronary events and mortality. *Arterioscler Thromb Vasc Biol.* 2019 May;39(5):925-933.
13. Gonzalez M, Sjölin I, Bäck M, Ögmundsdottir Michelsen H, Tanha T, Sandberg C, **Schiopu A**, Leosdottir M: Effect of a lifestyle-focused electronic patient support application for improving risk factor management, self-rated health, and prognosis in post-myocardial infarction patients: study protocol for a multi-center randomized controlled trial. *Trials.* 2019 Jan 24;20(1):76.
14. Ögmundsdottir Michelsen H, Nilsson M, Scherstén F, Sjölin I, **Schiopu A**, Leosdottir M: Tailored nurse-led cardiac rehabilitation after myocardial infarction results in better risk factor control at one year compared to traditional care: a retrospective observational study. *BMC Cardiovasc Disord.* 2018 Aug 15;18(1):167.
15. Lagerstedt JO, Dalla-Riva J, Marinkovic G, Del Giudice R, Engelbertsen D, Burlin J, Petrlova J, Lindahl M, Bernfur K, Melander O, Nilsson J, **Schiopu A**: Anti-apoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals. *J Intern Med.* 2019 Jan;285(1):49-58.
16. Grufman H, Yndigegn T, Gonçalves I, Nilsson J, **Schiopu A**: Elevated IL-27 in patients with acute coronary syndrome is associated with adverse ventricular remodeling and increased risk of recurrent myocardial infarction and cardiovascular death. *Cytokine.* 2019 Oct;122:154208.
17. Jonasson L, Grauen Larsen H, Lundberg AK, Gullstrand B, Bengtsson AA, **Schiopu A**: Stress-induced release of the S100A8/A9 alarmin is elevated in coronary artery disease patients with impaired cortisol response. *Sci Rep.* 2017 Dec 13;7(1):17545.
18. Engelbertsen D, Rattik S, Wigren M, Vallejo J, Marinkovic G, **Schiopu A**, Björkbacka H, Nilsson J, Bengtsson E: IL-1R and MyD88 signaling in CD4+ T cells promote Th17 immunity and atherosclerosis. *Cardiovasc Res.* 2018 Jan 1;114(1):180-187.

19. Mokhtari A, Lindahl B, **Schiopu A**, Yndigegn T, Khoshnood A, Gilje P, Ekelund U: A 0h/1h protocol for safe early discharge of chest pain patients. *Acad Emerg Med*. 2017 Aug; 24(8):983-992.
20. **Schiopu A**, Bengtsson E, Gonçalves I, Nilsson J, Fredrikson GN, Björkbacka H: Associations Between Macrophage Colony-Stimulating Factor and Monocyte Chemotactic Protein 1 in Plasma and First-Time Coronary Events: A Nested Case-Control Study. *J Am Heart Assoc*. 2016 Sep 13;5(9).
21. Dias JA, Wirfält E, Drake I, Gullberg B, Hedblad B, Persson M, Engström G, Nilsson J, **Schiopu A**, Nordin Fredrikson G, Björkbacka H: A high quality diet is associated with reduced systemic inflammation in middle-aged individuals. *Atherosclerosis*. 2015 Jan;238(1):38-44.
22. Rattik S, Wigren M, Björkbacka H, Fredrikson GN, Hedblad B, Siegbahn A, Bengtsson E, **Schiopu A**, Edsfeldt A, Dunér P, Grufman H, Gonçalves I, Nilsson J: High plasma levels of heparin-binding epidermal growth factor are associated with a more stable plaque phenotype and reduced incidence of coronary events. *Arterioscler Thromb Vasc Biol*. 2015 Jan;35(1):222-8.
23. Grufman H*, **Schiopu A***, Edsfeldt A, Björkbacka H, Nitulescu M, Nilsson M, Persson A, Nilsson J, Gonçalves I: Evidence for Altered Inflammatory and Repair Responses in Symptomatic Carotid Plaques from Elderly Patients. *Atherosclerosis*. 2014 Nov;237(1):177-82. *These authors have contributed equally to the work.
24. Örbom A, Jansson B, **Schiopu A**, Evans Axelsson S, Nilsson J, Nordin Fredrikson G, Strand SE: Multi-Radionuclide Digital Autoradiography of the Intra-Aortic Distribution of a Monoclonal Antibody Targeting Oxidized Low-Density Lipoprotein in Atherosclerotic Plaques. *Am J Nucl Med Mol Imaging*. 2014 Mar 20;4(2):172-80.
25. Cotoi OS, Dunér P, Ko N, Hedblad B, Nilsson J, Björkbacka H, **Schiopu A**: Plasma S100A8/A9 Correlates With Blood Neutrophil Counts, Traditional Risk Factors, and Cardiovascular Disease in Middle-Aged Healthy Individuals. *Arterioscler Thromb Vasc Biol*. 2014 Jan;34(1):202-10.
26. Cotoi OS, Manjer J, Hedblad B, Engström G, Melander O, **Schiopu A**: Procalcitonin predicts all-cause and cancer mortality in apparently healthy men: a prospective population-based study. *BMC Med*. 2013 Aug 13;11:180.
27. **Schiopu A**, Hedblad B, Engström G, Struck J, Morgenthaler NG, Melander O: Plasma procalcitonin and the risk for cardiovascular events and death – a prospective population-based study. *J Intern Med*. 2012 Nov;272(5):484-91.
28. Hester J*, **Schiopu A***, Nadig SN, Wood KJ: Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. *Am J Transplant*. 2012 Aug;12(8):2008-16. *equal contribution.
29. **Schiopu A**, Nadig SN, Cotoi OS, Hester J, van Rooijen H, Wood KJ: Inflammatory Ly-6Chi monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients. *Atherosclerosis*. 2012 Aug;223(2):291-8.

30. Feng G, Nadig SN, Bäckdahl L, Beck S, Francis RS, **Schiopu A**, Whatcott A, Wood KJ, Bushell A: Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. *Science Translational Medicine* 3, 83ra40 (2011).
31. Stollenwerk MM, Svensson O, **Schiopu A**, Jansson B, Arnebrant T, Fredrikson GN: Adsorption of low-density lipoprotein, its oxidation, and subsequent binding of specific recombinant antibodies: An in situ ellipsometric study. *Biochim Biophys Acta. Feb;1810(2):211-7.*
32. Nadig SN, Więckiewicz J, Wu DG, Warnecke G, Zhang W, Luo S, **Schiopu A**, Taggart DP, Wood KJ: In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. *Nature Medicine*. 2010 Jul;16(7):809-13.
33. **Schiopu A**, Jansson B, Söderberg I, Ljungkrantz I, Ares MPS, Carlsson R, Araya Z, Shah PK, Nilsson J & Nordin Fredrikson G: Recombinant antibodies to an oxidized LDL epitope induce rapid regression of atherosclerosis in *Apobec-1^{-/-}/LDL receptor^{-/-}* mice. *J Am Coll Cardiol*. 2007 Dec 11;50(24):2313-8.
34. Nordin Fredrikson G, Hedblad B, Berglund G, Alm R, Nilsson J-Å, **Schiopu A**, Shah PK, Nilsson J: Association between IgM against an aldehyde-modified peptide sequence in ApoB-100 and progression of carotid disease. *Stroke*. 2007 May;38(5):1495-500.
35. Nordin Fredrikson G, **Schiopu A**, Berglund G, Alm R, Nilsson J-Å, Shah P.K, Nilsson J: Antibody against the amino acid sequence 661-680 in ApoB-100 is associated with decreased carotid stenosis and cardiovascular events. *Atherosclerosis*. 2007 Oct;194(2):e188-92.
36. Ström A, Nordin Fredrikson G, **Schiopu A**, Söderberg I, Jansson B, Carlsson R, Hultgårdh Nilsson A & Nilsson J: Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100. *Atherosclerosis*. 2007 Feb;190(2):298-305.
37. Stollenwerk M, **Schiopu A**, Slotte JP, Nordin Fredrikson G, Dichtl W, Nilsson J, Ares MPS: VLDL potentiates LPS-induced TNF expression in macrophages. *Atherosclerosis*. 2005;179(2):247-54.
38. **Schiopu A**, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares MPS, Shah PK, Carlsson R, Nilsson J, Nordin Fredrikson G: Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. *Circulation*. 2004;110:2047-2052.

Manuscripts

1. Grauen Larsen H, Sun J, Sjögren M, Borné Y, Engström G, Nilsson P, Orho-Melander M, Goncalves I, Nilsson J, Melander O, **Schiopu A**: The Gly82Ser polymorphism in

the receptor for advanced glycation end products increases the risk for coronary events in the general population - *Submitted*

2. Yndigegn T, Grufman H, Erlinge D, Nilsson J, Goncalves I, **Schiopu A**: Elevated CA125 is associated with incident heart failure and increased mortality in patients with acute coronary syndrome - *Submitted*
3. Yndigegn T, Koul S, Omerovic E, Sarno G, Linder R, Fröbert O, Jensen J, Rylance R, **Schiopu A**, Erlinge D, Göteborg M: Long-term safety of revascularization deferral based on instantaneous wave-free ratio or fractional flow reserve- a SWEDEHEART registry study
4. Yndigegn T, Grufman H, Erlinge D, Nilsson J, Goncalves I, **Schiopu A**: FGF23 is associated with heart failure independent of traditional risk factors and prognostic biomarkers in acute coronary syndrome patients with normal kidney function
5. **Schiopu A**, Collén A, Ongstad E, Varma V, Goncalves I, Gan LM, Nilsson J: Elevated soluble lectin-like oxidized low-density lipoprotein receptor-1 (LOX1) in plasma is associated with increased risk for heart failure after an acute coronary event
6. Manea S, Simionescu M, **Schiopu A***, Manea A*: Pharmacological inhibition of the alarmin S100A9 reduces NADPH oxidase expression and the levels of reactive oxygen species and inflammatory cytokines in the ischemic myocardium. **Equal contribution*
7. Suica V, Boteanu R, Simionescu M, **Schiopu A***, Antohe F*: Inhibition of S100A9 in myocardial infarction prevents left ventricular remodelling – a proteomics study. **Equal contribution*

Review articles

1. Mares RG, Marinkovic G, Cotoi OS, **Schiopu A**: Innate immune mechanisms in myocardial infarction - An update. *Revista Romana de Medicina de Laborator*, 2018.
2. **Schiopu A**, Cotoi OS: S100A8 and S100A9 – DAMPs at the crossroads between innate immunity, traditional risk factors and cardiovascular disease. *Mediators of Inflammation*, vol. 2013, Article ID 828354, 2013.
3. **Schiopu A**, Cotoi OS, Wood KJ: Ly-6C(hi) monocytes: a potential target for preventing transplant arteriosclerosis? *Expert Rev Clin Immunol*. 2013 Jan;9(1):5-7.
4. Issa F*, **Schiopu A***, Wood KJ: Role of T cells in graft rejection and transplantation tolerance. *Expert Rev Clin Immunol*. 2010 Jan;6(1):155-69. **These authors have contributed equally to the work.*
5. **Schiopu A**, Wood KJ: Regulatory T cells: hypes and limitations. *Curr Opin Organ Transplant*. 2008 Aug;13(4):333-8.

6. Nilsson J, Nordin Fredrikson G, **Schiopu A**, Shah PK, Jansson B, Carlsson R: Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease. *Curr Pharm Des.* 2007;13(10):1021-30.

Books

1. Hecser L, **Schiopu A** – Atherosclerosis and endocarditis – pathological complexity. *University Press Targu-Mures, Romania, 2009.*

Selected conference presentations

1. Marinkovic G, De Camp L, Winkler L, Mares RG, Szabo IA, Cotoi OS, Nilsson J, Jovinge S, **Schiopu A**: The neutrophil mediator S100A9 is a key promoter of cardiac repair after myocardial infarction – *International Society for Heart Research congress, Beijing 2019*
2. **Schiopu A**, Marinkovic G, De Camp L, Winkler L, Mares RG, Szabo IA, Goncalves I, Nilsson J, Jovinge S: Inhibition of the pro-inflammatory neutrophil mediator S100A8/A9 alleviates heart failure development post-myocardial infarction – *Heart Failure Winter Research Meeting 2019 and 6th World Congress on Acute Heart Failure, Athens 2019*
3. **Schiopu A**, Marinković G, DeCamp L, Winkler L, Nilsson J, Jovinge S: The S100A8/A9 alarmin stimulates myeloid cell response and promotes cardiac repair after myocardial infarction – *European Atherosclerosis Society Congress, Lisbon 2018 – Oral presentation*
4. **Schiopu A**, Marinković G, DeCamp L, Winkler L, Mares R, Cotoi OS, Nilsson J, Jovinge S: Short-term blockade of the S100A8/A9 alarmin in the immediate post-myocardial infarction period inhibits acute myocardial inflammation and preserves myocardial repair - *European Society of Cardiology Congress, Barcelona, 2017 – Winner “Moderated Poster Award” competition*
5. **Schiopu A**, Yndigegn T, Grufman H, Nilsson J, Goncalves I: Galectin 3 is a powerful risk predictor for recurrent coronary events in acute coronary syndrome patients – *European Society of Cardiology Congress, London, 2015*
6. **Schiopu A**, Bengtsson E, Goncalves I, Nilsson J, Fredrikson GN, Björkbacka H: MCP-1 and M-CSF Are Strong Predictors of First-Time Myocardial Infarction in the General Population – *Arteriosclerosis Thrombosis and Vascular Biology Scientific Sessions, San Francisco, USA, 2015*
7. **Schiopu A**, Cotoi OS, Ko N, Dunér P, Björkbacka H, Hedblad B, Nilsson J: S100A8/A9, potentially important link between circulating neutrophils, traditional CV risk factors and CV risk in apparently healthy women – *European Society of Cardiology Congress, Barcelona, 2014*

8. **Schiopu A**, Cotoi OS, Björkbacka H, Nilsson J: The neutrophil activation marker MRP8/14 correlates with carotid plaque area and predicts cardiovascular events in healthy individuals – *European Atherosclerosis Society Congress, Lyon, 2013*
9. **Schiopu A**, Cotoi OS, Ko N, Dunér P, Björkbacka H, Hedblad B, Nilsson J: Circulating Neutrophils and their Secreted Mediator S100A8/A9 Correlate with Carotid Artery Disease and Predict Cardiovascular Events in Healthy Individuals – *Arteriosclerosis Thrombosis and Vascular Biology Scientific Sessions, Orlando, USA, 2013*
10. **Schiopu A**, Hedblad B, Engström G, Struck J, Morgenthaler NG, Melander O: Plasma procalcitonin and the risk for cardiovascular events and death – a prospective population-based study - *European Atherosclerosis Society Congress, Milano, 2012*
11. **Schiopu A**, Nadig S, Wood JK: Plasma cholesterol accelerates transplant arteriosclerosis and chronic rejection through increased recruitment of inflammatory monocytes into the arterial wall - *Internatinoal Congress of The Transplantation Society, Vancouver, 2010*
12. **Schiopu A**, Nadig S, Wood JK: Plasma lipids infiltrate arterial allografts and accelerate the development of transplant arteriosclerosis. - *International Congress of The Transplantation Society, Sydney, 2008 - Oral presentation*
13. **Schiopu A**, Jansson B, Shah P, Carlsson R, Nilsson J, Nordin Fredrikson G: Plaque regression induced by human recombinant antibodies against oxidized low density lipoproteins in LDLR^{-/-} Apobec-1 double knockout mice. *Poster of Distinction - Annual meeting of the Federation of Clinical Immunology Societies (FOCIS), San Francisco, 2006*
14. **Schiopu A**, Carlsson R, Nilsson J, Nordin Fredrikson G: IgG1 antibodies against oxLDL epitopes induce regression of atherosclerosis in LDLR^{-/-} Apobec mice with advanced disease. *Young Investigator Award finalist - European Atherosclerosis Society Congress, Prague, 2005*
15. **Schiopu A**, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares MPS, Shah PK, Carlsson R, Nilsson J, Nordin Fredrikson G: Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis – *Young Investigator Award - European Atherosclerosis Society Congress, Sevilla, 2004*